Skip to main content

Table 1 Patient characteristics

From: SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells

Patient

Age

Sex

Disease status

Karyotype

ELN genetic group

FLT3-ITD

NPM1

0276

29

F

ID

Aberrant

Adverse

wt

wt

2562

52

M

ID

Intermediate aberrant

n.a.

wt

wt

3140

74

M

ID

Normal

Intermediate

wt

wt

3073

54

M

R

Normal

Favourable

wt

wt

1233

49

F

ID

Complex aberrant

Adverse

mut

mut

3826

85

M

ID

Aberrant

Adverse

wt

wt

2449

30

F

ID

Aberrant

Favourable

wt

wt

4169

20

M

ID

Aberrant

Intermediate

wt

wt

0178

56

F

ID

Complex aberrant

Favourable

wt

wt

3386

52

M

ID

Normal

Favourable

wt

mut

3776

35

F

ID

Normal

Favourable

wt

wt

3221

59

M

ID

Normal

Favourable

wt

mut

3495

58

M

ID

Normal

Favourable

mut

wt

0885

74

F

ID

Normal

Intermediate

mut

mut

4321

50

F

ID

Normal

Intermediate

mut

mut

6789

68

M

ID

Normal

Favourable

mut

wt

0252

84

F

ID

Aberrant

Favourable

mut

mut

1421

66

F

ID

Aberrant/normal

Adverse

wt

wt

0682

56

F

ID

Complex aberrant

Adverse

wt

wt

7782

76

M

ID

Complex aberrant

Adverse

wt

wt

5964

87

F

ID

Complex aberrant

Adverse

wt

wt

AML-491 [3]

53

F

R

del(7)(q21)

Adverse

wt

wt

AML-579 [3]

51

M

R

Normal

Adverse

mut, LOH

mut

AML-640

79

M

R

t(11;15)

Intermediate

mut

mut

AML-979

56

F

R

Normal

n.a.

wt + mut subclone

mut

  1. European LeukemiaNet (ELN), initial diagnosis (ID), relapse (R), not available (n.a.), wild type (wt), mutated (mut), loss of heterozygosity (LOH), female (F), male (M)